What is the price-to-earnings ratio of Healios KK?
The price-earnings ratio of Healios KK is currently 12.31.
Healios KK P/S 2024
Healios KK P/S
12.31
Ticker
4593.T
ISIN
JP3835100003
WKN
A14U80
As of Nov 4, 2024, Healios KK's P/S ratio stood at 12.31, a -92.42% change from the 162.42 P/S ratio recorded in the previous year.
The Healios KK P/S history
Healios KK Aktienanalyse
What does Healios KK do?
Healios KK is a Japanese company founded in 2011. It focuses on the development of neuroscience, particularly the treatment of central nervous system disorders. Healios KK is headquartered in Tokyo and currently employs approximately 100 employees. Business Model: Healios KK aims to develop and market innovative treatments for patients with neurological disorders. The company works closely with research institutes, universities, and other companies to make progress in the development of new drugs and therapies. Healios KK is also involved in clinical research and works to translate its research findings into new products. Divisions: The company focuses on four main areas: - Regenerative Medicine - Stem Cell Therapy - Brain-Computer Interfaces - AI-supported Diagnosis Regenerative Medicine: Healios KK researches new technologies for the treatment of neurological disorders through regenerative medicine, particularly through stem cell therapy. The company collaborates closely with researchers to develop groundbreaking technologies that support the healing of nerve cells and promote brain regeneration. Stem Cell Therapy: Healios KK also focuses on stem cell therapy, which is being investigated in the company's research labs to find new treatment options for patients with spinal injuries, strokes, Parkinson's, and other neurological disorders. Stem cell therapy involves using stem cells to regenerate damaged tissue in the brain or spinal cord. Brain-Computer Interfaces: Healios KK is also working on the development of brain-computer interfaces (BCIs) that aim to establish a direct connection between the brain and a computer. With the help of these interfaces, patients with paralysis or certain neurological disorders can regain control over their movements and activities. Healios KK has developed a smartglove that can be controlled using BCI. AI-supported Diagnosis: Using state-of-the-art artificial intelligence (AI) technologies, Healios KK is developing new and more effective diagnostic methods for neurological disorders. By developing algorithms based on brain scan images, AI-supported diagnoses are expected to be faster and more effective in the future. Products: Healios KK offers a wide range of products and therapies to effectively treat patients with neurological disorders. These include: - Stem Cell Therapy: The company develops and distributes stem cell therapies to treat patients with spinal injuries, strokes, and other neurological disorders. - Smartglove: Healios KK has developed an intelligent glove that is controlled through brain-computer interfaces. The glove is intended for patients who are unable to move their hands due to paralysis. - AI-supported Diagnosis: The company is working on computer-assisted diagnoses of neurological disorders that are more effective and accurate than conventional diagnoses. - Clinical Trials: Healios KK also conducts clinical trials to investigate the effectiveness of new therapies and treatment methods. Summary: Healios KK is a Japanese company focused on developing innovative therapies and treatment methods for neurological disorders. The company works closely with research institutes and other companies to make progress in the development of new drugs and therapies. Healios KK has four main divisions: Regenerative Medicine, Stem Cell Therapy, Brain-Computer Interfaces, and AI-supported Diagnosis. The company offers a variety of products, including stem cell therapy, smartgloves, and AI-supported diagnoses. Healios KK aims to enhance the lives of patients with neurological disorders by using innovative technologies to support their health. Healios KK ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Healios KK's P/S Ratio
Healios KK's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Healios KK's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Healios KK's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Healios KK’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Healios KK stock
How has the price-earnings ratio of Healios KK changed compared to last year?
The price-to-earnings ratio of Healios KK has increased by -92.42% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Healios KK high compared to other companies?
Yes, the price-to-earnings ratio of Healios KK is high compared to other companies.
How does an increase in the price-earnings ratio of Healios KK affect the company?
An increase in the price-earnings ratio of Healios KK would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Healios KK affect the company?
A decrease in the price-earnings ratio of Healios KK would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Healios KK?
Some factors that influence the price-earnings ratio of Healios KK are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Healios KK pay?
Over the past 12 months, Healios KK paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Healios KK is expected to pay a dividend of 0 JPY.
What is the dividend yield of Healios KK?
The current dividend yield of Healios KK is .
When does Healios KK pay dividends?
Healios KK pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Healios KK?
Healios KK paid dividends every year for the past 0 years.
What is the dividend of Healios KK?
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
In which sector is Healios KK located?
Healios KK is assigned to the 'Health' sector.
Wann musste ich die Aktien von Healios KK kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Healios KK from 11/4/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 11/4/2024.
When did Healios KK pay the last dividend?
The last dividend was paid out on 11/4/2024.
What was the dividend of Healios KK in the year 2023?
In the year 2023, Healios KK distributed 0 JPY as dividends.
In which currency does Healios KK pay out the dividend?
The dividends of Healios KK are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Healios KK
Our stock analysis for Healios KK Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Healios KK Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
